Search results
Results from the WOW.Com Content Network
A nosebleed, also known as epistaxis, is an instance of bleeding from the nose. [1] Blood can flow down into the stomach, and cause nausea and vomiting. [8] In more severe cases, blood may come out of both nostrils. [9] Rarely, bleeding may be so significant that low blood pressure occurs. [1]
A nosebleed (epistaxis) usually occurs in the anterior part of the nose from an area known as Kiesselbach's plexus which consists of arteries. Woodruff's plexus is a venous plexus in the posterior part and a nosebleed here accounts for only between 5 and 10 per cent of nosebleeds. Older adults are most often affected. [5]
Patient.info is an online resource providing information on health, lifestyle, disease and other medical related topics. The website's aim is to provide members of the public with up-to-date information on health related topics in the form of comprehensive leaflets (which can be read online or printed), blogs, wellbeing advice and videos.
The sphenopalatine artery is the artery commonly responsible for epistaxis (difficult to control bleeding of the nasal cavity, especially the posterior nasal cavity). [3] In severe nose bleed cases which do not stop after intense packing of anti-clotting agents, the sphenopalatine artery can be ligated (clipped and then cut) during open surgery ...
In most cases of sinus barotrauma, localized pain to the frontal area is the predominant symptom. This is due to pain originating from the frontal sinus, it being above the brow bones. Less common is pain referred to the temporal, occipital, or retrobulbar region. Epistaxis or serosanguineous secretion from the nose may occur.
Ninety percent of nosebleeds (epistaxis) occur in Kiesselbach's plexus, whereas five to ten percent originate from Woodruff's plexus. [3] It is exposed to the drying effect of inhaled air. [3] It can also be damaged by trauma from a finger nail (nose picking), as it is fragile. [3] [4] It is the usual site for nosebleeds in children and young ...
The SPC is not intended to give general advice about treatment of a condition but does state how the product is to be used for a specific treatment. It forms the basis of information for health professionals to know how to use the specific product safely and effectively. The package leaflet supplied with the product is aimed at end-users. [3]
Luspatercept is indicated for the treatment of adults with transfusion-dependent anemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy.